Foxcroft
Therapeutics
Advancing Immuno-Oncology Through Targeted Vaccine Technology.
We are a pre-clinical vaccine technology company developing targeted, tumor lysate–based cancer vaccines. Founded in 2025, we utilize cutting-edge delivery vehicles to redefine treatment efficacy.
Engineered for Precision.
Licensed exclusively from Tufts University in September 2025, our global cancer vaccine platform is engineered to stimulate targeted, robust immune responses against tumor-derived antigens.
Optimized Delivery.
Efficacy requires precision. Through our March 2026 sublicense agreement with Hopewell Therapeutics, we leverage proprietary tissue-targeting lipid nanoparticles (ttLNPs). This ensures optimal delivery of our vaccines directly to lymph nodes, maximizing the immune response.
The Path Forward
Moving rapidly beyond pre-clinical development, Foxcroft is currently preparing to advance its groundbreaking formulations into large-mammal studies, beginning with a canine clinical trial.